Rett Syndrome Pipeline Insights Report, 2020

Dublin, Feb. 19, 2020 (GLOBE NEWSWIRE) -- The "Rett Syndrome - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Rett Syndrome Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Rett Syndrome market.

A detailed picture of the Rett Syndrome pipeline landscape is provided, which includes the disease overview and Rett Syndrome treatment guidelines. The assessment part of the report embraces in-depth Rett Syndrome commercial assessment and clinical assessment of the Rett Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rett Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The report provides insights into:

• All of the companies that are developing therapies for the treatment of Rett Syndrome with aggregate therapies developed by each company for the same.
• Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Rett Syndrome treatment.
• Rett Syndrome key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Rett Syndrome market.

Scope of the Report

• The Rett Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Rett Syndrome across the complete product development cycle, including all clinical and nonclinical stages.
• It comprises of detailed profiles of Rett Syndrome therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.
• Detailed Rett Syndrome research and development progress and trial details, results wherever available, are also included in the pipeline study.
• Coverage of dormant and discontinued pipeline projects along with the reasons if available across Rett Syndrome.

Key Topics Covered

1. Report Introduction

2. Rett Syndrome
2.1. Overview
2.2. History
2.3. Rett Syndrome Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Rett Syndrome Diagnosis
2.6.1. Diagnostic Guidelines

3. Rett Syndrome Current Treatment Patterns
3.1. Rett Syndrome Treatment Guidelines

4. Rett Syndrome - Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Rett Syndrome companies collaborations, Licensing, Acquisition - Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Rett Syndrome Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Rett Syndrome Acquisition Analysis

5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target

6. Rett Syndrome Late Stage Products (Phase-III)

7. Rett Syndrome Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Rett Syndrome Discontinued Products

13. Rett Syndrome Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table

14. Rett Syndrome Key Companies

15. Rett Syndrome Key Products

16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation

17. Rett Syndrome Unmet Needs

18. Rett Syndrome Future Perspectives

19. Rett Syndrome Analyst Review

20. Appendix

21. Report Methodology
21.1. Secondary Research
21.2. Expert Panel Validation

Companies Mentioned

• AMO Pharma Ltd.
• Amorsa Therapeutics Inc.
• Anavex Life Sciences Corp.
• ArmaGen Inc.
• ACADIA Pharmaceuticals Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/9clva9

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: 
CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900